Nanoviricides Inc (NNVC)

$1.59 +0.01 (0.63%)
Market Cap 25.39M
Revenue (ttm) 0.00
Net Income (ttm) -8.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 143,427
Avg Vol 287,776
Day's Range N/A - N/A
Shares Out 16.07M
Stochastic %K 9%
Beta 0.96
Analysts Strong Sell
Price Target $6.50

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 937 6137
Address:
1 Controls Drive, Shelton, United States
Love1010
Love1010 Aug. 1 at 6:34 PM
$NNVC brilliance again
0 · Reply
Love1010
Love1010 Aug. 1 at 6:15 PM
$NNVC the pumps get smaller and the dumps go deeper....this is the process of a company in the demise. You will see pennies forever at some point n
0 · Reply
Love1010
Love1010 Jul. 31 at 5:44 PM
$NNVC if you aren't seeing the bearish signals and change in trend, you aren't seeing!!
0 · Reply
Kewlpapa
Kewlpapa Jul. 30 at 8:08 PM
$NNVC picked up some shares today. Will continue to accumulate here
1 · Reply
The_Titan_Traders
The_Titan_Traders Jul. 30 at 3:01 PM
$NNVC long
1 · Reply
STRAYNUT
STRAYNUT Jul. 30 at 1:51 PM
$NNVC Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/measles-cases-increasing-worldwide-need-the-new-nv-387-broad-spectrum-1053451
0 · Reply
The_Titan_Traders
The_Titan_Traders Jul. 30 at 12:00 PM
$NNVC
0 · Reply
TradingSecretsYT
TradingSecretsYT Jul. 30 at 12:03 AM
We look at $NNVC NanoViricides which has a multi billion dollar potential and exclusive market with a HUGE number of catalysts including for 2025, https://youtu.be/_ND1pG8zeBY
0 · Reply
Mitch___Picks
Mitch___Picks Jul. 29 at 7:54 PM
$NNVC higher lows coming in, setting up nicely for a potential pop back over 2+. If they did not want this higher, I would assume this would have flushed already.
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jul. 29 at 4:58 PM
🚨🚨🚨 $NNVC On strong watch ! 🚨🚨🚨 🧬 Nanoviricides is a clinical‑stage biopharmaceutical company dedicated to developing nanomedicine-based antiviral therapies 📰Upcoming Catalyst: Company indicated a potential update on Phase II enrollment or top-line results expected in Q3 2025 📈On a technical standpoint, the share price is on an uptrend from end of June (1.15$ bottom) and is currently sitting at 1.70$. With major catalysts and updates coming up It wouldn't be surprising to see the price test the 2$ resistance. Website: https://nanoviricides.com Disclaimer: https://tinyurl.com/44h4kjaz #trading #stocks #advertisement $DRRX $RCON $STAI $SLRX
0 · Reply
Latest News on NNVC
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 30, 2025, 8:30 AM EDT - 5 days ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 23, 2025, 8:30 AM EDT - 12 days ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 21, 2025, 6:30 AM EDT - 14 days ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 19 days ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 18, 2025, 6:30 AM EDT - 6 weeks ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

NanoViricides Measles Drug Development Animal Study is Imminent

Jun 4, 2025, 6:55 AM EDT - 2 months ago

NanoViricides Measles Drug Development Animal Study is Imminent

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 28, 2025, 6:30 AM EDT - 2 months ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 22, 2025, 6:30 AM EDT - 2 months ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 14, 2025, 6:30 AM EDT - 2 months ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

May 5, 2025, 6:30 AM EDT - 3 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 29, 2025, 6:30 AM EDT - 3 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Apr 14, 2025, 6:30 AM EDT - 4 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 11, 2025, 6:30 AM EDT - 5 months ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Mar 4, 2025, 6:30 AM EST - 5 months ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 19, 2025, 6:30 AM EST - 5 months ago

NanoViricides, Inc. Has Filed its Quarterly Report

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Feb 11, 2025, 6:30 AM EST - 6 months ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 29, 2025, 6:30 AM EST - 6 months ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 27, 2025, 6:30 AM EST - 6 months ago

NanoViricides Engages CRO for Phase II Clinical Trial

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 13, 2025, 6:30 AM EST - 7 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Jan 8, 2025, 6:30 AM EST - 7 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Dec 23, 2024, 6:30 AM EST - 8 months ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 15, 2024, 6:30 AM EST - 9 months ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Nov 4, 2024, 12:00 AM EST - 9 months ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

NanoViricides President Dr. Diwan to Present at the PODD Conference

Oct 22, 2024, 6:30 AM EDT - 10 months ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Oct 15, 2024, 6:30 AM EDT - 10 months ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Oct 8, 2024, 6:30 AM EDT - 10 months ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Sep 30, 2024, 6:30 AM EDT - 11 months ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

Sep 26, 2024, 6:30 AM EDT - 11 months ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Aug 26, 2024, 7:30 AM EDT - 1 year ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Aug 19, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Aug 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

Aug 1, 2024, 6:30 AM EDT - 1 year ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

Jul 24, 2024, 6:30 AM EDT - 1 year ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

Jul 11, 2024, 6:30 AM EDT - 1 year ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

Jun 24, 2024, 6:00 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Jun 20, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

Jun 11, 2024, 6:30 AM EDT - 1 year ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

Jun 4, 2024, 6:30 AM EDT - 1 year ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

May 20, 2024, 6:30 AM EDT - 1 year ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

NanoViricides Has Filed its Quarterly Report

May 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Has Filed its Quarterly Report

A Novel Broad-Spectrum Antiviral with Activity Against RSV

May 14, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

May 10, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

May 8, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

May 6, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

Apr 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

Feb 15, 2024, 6:30 AM EST - 1 year ago

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Feb 1, 2024, 6:20 AM EST - 1 year ago

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

Jan 29, 2024, 6:30 AM EST - 1 year ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

NanoViricides to Present at the Biotech Showcase in San Fransisco

Jan 4, 2024, 6:30 AM EST - 1 year ago

NanoViricides to Present at the Biotech Showcase in San Fransisco

Love1010
Love1010 Aug. 1 at 6:34 PM
$NNVC brilliance again
0 · Reply
Love1010
Love1010 Aug. 1 at 6:15 PM
$NNVC the pumps get smaller and the dumps go deeper....this is the process of a company in the demise. You will see pennies forever at some point n
0 · Reply
Love1010
Love1010 Jul. 31 at 5:44 PM
$NNVC if you aren't seeing the bearish signals and change in trend, you aren't seeing!!
0 · Reply
Kewlpapa
Kewlpapa Jul. 30 at 8:08 PM
$NNVC picked up some shares today. Will continue to accumulate here
1 · Reply
The_Titan_Traders
The_Titan_Traders Jul. 30 at 3:01 PM
$NNVC long
1 · Reply
STRAYNUT
STRAYNUT Jul. 30 at 1:51 PM
$NNVC Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/measles-cases-increasing-worldwide-need-the-new-nv-387-broad-spectrum-1053451
0 · Reply
The_Titan_Traders
The_Titan_Traders Jul. 30 at 12:00 PM
$NNVC
0 · Reply
TradingSecretsYT
TradingSecretsYT Jul. 30 at 12:03 AM
We look at $NNVC NanoViricides which has a multi billion dollar potential and exclusive market with a HUGE number of catalysts including for 2025, https://youtu.be/_ND1pG8zeBY
0 · Reply
Mitch___Picks
Mitch___Picks Jul. 29 at 7:54 PM
$NNVC higher lows coming in, setting up nicely for a potential pop back over 2+. If they did not want this higher, I would assume this would have flushed already.
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jul. 29 at 4:58 PM
🚨🚨🚨 $NNVC On strong watch ! 🚨🚨🚨 🧬 Nanoviricides is a clinical‑stage biopharmaceutical company dedicated to developing nanomedicine-based antiviral therapies 📰Upcoming Catalyst: Company indicated a potential update on Phase II enrollment or top-line results expected in Q3 2025 📈On a technical standpoint, the share price is on an uptrend from end of June (1.15$ bottom) and is currently sitting at 1.70$. With major catalysts and updates coming up It wouldn't be surprising to see the price test the 2$ resistance. Website: https://nanoviricides.com Disclaimer: https://tinyurl.com/44h4kjaz #trading #stocks #advertisement $DRRX $RCON $STAI $SLRX
0 · Reply
Bullish_Trade
Bullish_Trade Jul. 29 at 4:46 PM
$NNVC on watch over the $1.78/$1.80 level $1.92/$2 test once that clears
0 · Reply
Maximus_Trading
Maximus_Trading Jul. 29 at 4:44 PM
$NNVC on watch. Volume starting to come in. Key levels to break at the moment are 1.79 followed by 1.92
0 · Reply
StocksWithFlav
StocksWithFlav Jul. 29 at 4:31 PM
$NNVC watch for a move over 1.75
0 · Reply
STRAYNUT
STRAYNUT Jul. 24 at 7:21 PM
$NNVC Short Interest (07/15/25) Shares Sold Short 105,963 Change from Last -56.22% Percent of Float 0.68% https://finviz.com/quote.ashx?t=NNVC&p=d RATS ARE JUMPING SHIP!
0 · Reply
ZacksSCR
ZacksSCR Jul. 24 at 2:52 PM
$NNVC
0 · Reply
Love1010
Love1010 Jul. 23 at 2:52 PM
$NNVC calling all suckers
0 · Reply
drkazmd65
drkazmd65 Jul. 23 at 2:31 PM
$NNVC - Beating the drum again. https://www.morningstar.com/news/accesswire/1051828msn/nanoviricides-discusses-the-multi-billion-dollar-potential-of-its-broad-spectrum-drug-nv-387-its-effectiveness-against-influenza-coronaviruses-rsv-mpox-and-now-measles-expected-to-drive-value
0 · Reply
ZacksSCR
ZacksSCR Jul. 23 at 12:54 PM
A new antiviral class. A Phase 2 trial for deadly Mpox Clade I. A platform with multi-virus potential. $NNVC is one to watch. https://youtu.be/ZvLpA9p8h9M #NNVC #Biotech #SmallCapStocks #Antivirals #ClinicalTrials #Mpox #HealthcareInnovation
1 · Reply
tomzprofit
tomzprofit Jul. 22 at 10:28 PM
$NNVC Some of its patents run out in 2026 and 2027. I haven't read how far intellectual property will carry them. NNVC may decide to first apply for orphan drug status in the US for rare monkey pox, which will guarantee it 5 years of FDA protection.
0 · Reply
STRAYNUT
STRAYNUT Jul. 22 at 10:15 PM
$NNVC NNVC @ Straynut: July 22, 2025: Regarding the invested capital of $150 million, the current market value of Nano is roughly $25 million, which is the appraised value of the lab if sold separately, meaning the entire value of this priceless NV-387 therapeutic technology, 30 years in the making, is ZERO. NONSENSE!
0 · Reply
JStar777
JStar777 Jul. 22 at 7:14 PM
@Stock_Catcher $NNVC
0 · Reply
STRAYNUT
STRAYNUT Jul. 22 at 2:13 PM
$NNVC @ Straynut: July 22, 2025: It gets even better! "NV-387 is expected to become an "emperic therapy" for any/all viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections. Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection. This has tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection". (NNVC PR of 5-28-2025.)
0 · Reply